Cgrp antagonists for treating migraine breakthrough
AssigneeBiohaven Pharmaceutical Holding Company Ltd.
InventorsVladimir Coric, Robert Croop
Life of this patent
Estimating the term…
Abstract
Disclosed are methods of treating breakthrough migraine in patients using breakthrough CGRP antagonists. Also disclosed are methods for the prophylactic treatment of migraine.
Claims20
A method for treating, preventing, alleviating or reducing the frequency of occurrence of headache in a patient in need thereof, comprising administering to the patient rimegepant, wherein said patient is concurrently undergoing treatment with a clostridial derivative.
A method for treating, preventing, alleviating or reducing the frequency of occurrence of migraine or a symptom of migraine in a patient in need thereof, comprising administering to the patient rimegepant, wherein said patient is concurrently undergoing treatment with a clostridial derivative.
A method for treating, preventing, alleviating or reducing the frequency of occurrence of headache in a patient in need thereof, comprising administering to the patient zavegepant, wherein said patient is concurrently undergoing treatment with a clostridial derivative.
A method for treating, preventing, alleviating or reducing the frequency of occurrence of migraine or a symptom of migraine in a patient in need thereof, comprising administering to the patient zavegepant, wherein said patient is concurrently undergoing treatment with a clostridial derivative.
Dependencies are inferred from the claim text.